.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Understanding the Black Box Warnings for JAK Inhibitors

Linda Stein Gold, MD, and Matthew Zirwas, MD, provide a discussion on the role of JAK inhibitors in inflammatory diseases.

EP. 1: An Overview of JAK Inhibitors

December 22nd 2021

Linda Stein Gold, MD, provides an overview of the four JAK inhibitors currently available for treating inflammatory diseases.

EP. 2: Safety and Efficacy of JAK Inhibitors

January 3rd 2022

Key opinion leaders explain the box warnings and safety profiles of JAK inhibitors.

EP. 3: Reviewing Clinical Trial Data for JAK Inhibitors

January 5th 2022

Matthew Zirwas, MD, breaks down the safety of JAK inhibitors based on clinical trial data.

EP. 4: Risk of Systemic Absorption with JAK Inhibitors

January 17th 2022

Clinicians provide insight into the risk of high systemic absorption levels with JAK inhibitor treatments.

EP. 5: Treating Atopic Dermatitis with Ruxolitinib

January 19th 2022

Dr Matthew Zirwas describes his experience using JAK inhibitor ruxolitinib in his clinical practice.

EP. 6: Advice for Clinicians on JAK Inhibitors

January 26th 2022

Linda Stein Gold, MD, and Matthew Zirwas, MD, share some advice for clinicians on how to discuss JAK inhibitors with patients.

EP. 7: How to Explain JAK Inhibitor Warnings to Patients

February 2nd 2022

Experts outline strategies for patient conversations around the black box warning.